Search

September 18, 2016—Drug therapy with beta-blockers represents the therapeutic mainstay for both LQTS and CPVT. The goal of the document is to help clinicians understand the importance of beta-blocker therapy in these two genetic disorders, as well as to provide clinical guidance on the choice of agents. Nadolol, when available, has been the preferred beta-blocker utilized by the largest LQTS/CPVT specialty centers throughout the world for the past 25 years.

The Heart Rhythm Society (HRS) offers its guidance through scientific and clinical documents to provide three main components vital to advancements in the heart rhythm field: analysis, discussion of current issues, and suggestions for clinical application. HRS documents provide guidance to our membership and other entities on issues that are timely and for which guidance is currently lacking or needs to be updated.

June 10, 2016—Ventricular cardiomyopathies have been well classified; however, a definition and detailed analysis of atrial cardiomyopathy are lacking from the literature. The purpose of the present consensus report was to define atrial cardiomyopathy, to review the relevant literature, and to consider the impact of atrial cardiomyopathies on arrhythmia management and stroke.

This document has been retired and replaced by "2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation."

March 5, 2012—The purpose of the 2012 Consensus Statement is to provide a state-of-the-art review of the field of catheter and surgical ablation of atrial fibrillation. It reports on the findings of a Task Force, convened by the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), and the European Cardiac Arrhythmia Society (ECAS) and charged with defining the indications, techniques, and outcomes of this procedure.

This document has been retired and replaced by "2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation."

February 14, 2011—This guideline update states that dabigatran, a new antithrombotic agent that was recently approved by the U.S. Food and Drug Administration, is an alternative to warfarin to help prevent dangerous blood clots in patients with atrial fibrillation. The update is a joint publication of the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the Heart Rhythm Society (HRS). 

This document has been retired and replaced by "2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation."

December 20, 2010—This guideline update is based on a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.